semaglutide patent expiry Last week's of the for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Following the patent expiry of

However, due to concerns for safety, quality, and effectiveness of compounded GLP1RAs, the American Diabetes Association (ADA) has issued guidance recommending switching individuals to different FDA-approved medications to achieve and maintain individualized glucose-lowering, weight management, and/or cardiovascular and kidney risk reduction goals when supply or access is limited [75]

GLP-1 receptor-agonist weight loss reduces fat but also a meaningful proportion of lean muscle mass

Adams B

Very Rare Side Effects Some study participants reported mild injection-site irritation, including temporary sensitivity or tingling in a small number of cases

Pontifex MG, Malik M, Connell E, Muller M, Vauzour D